EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Elevai Labs, Inc. (ELAB) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Elevai Labs, Inc. $1.93, price $3.36, upside -42.6%, quality 19 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US28622K1043

EL Elevai Labs, Inc. logo Thin data Oct 4, 2026

Elevai Labs, Inc.

ELAB · US

Weakest SetupStrongly overvalued and low quality.

Mixed vs. peers (3/7)
Fair value $1.93 · Strongly overvalued (−42.6%)
Quality 19/100
Weak Growth (revenue 3y −8.3 %/yr in USD)
Negative free cash flow
Narrow moat 3/100
Thin data
⚠ Dilution
Watch Elevai Labs, Inc. Common Stock for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$1,000,000 $3.23 Fair Value $1.93 Nov 2023 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.

How to read this chart

34‑month range $3.23 – $1,000,000 · fair‑value band $1.28 – $2.41 · the $3.36 price screens above the $1.93 fair value. Dashed = 300-day average. As of Oct 4, 2026.

Follow Elevai Labs, Inc. Common Stock in your weekly email

Every Wednesday you see whether Elevai Labs, Inc. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining.

Show more

PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operating investment firms; providing packaging solutions to industrial and consumer markets; and design and production of high-tolerance components for industrial and technological applications. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.

Stock analysis

Elevai Labs, Inc. Common Stock (ELAB) currently trades at $3.36, while our model-based Fair Value estimate is $1.93, 42.6% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: $1.28 (bear) to $2.41 (bull), the price of $3.36 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 19/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Elevai Labs, Inc. Common Stock reported revenue of $590K in FY2025 versus $827 in FY2021, a compound +416.8%/yr. Reported net income was −$7.7M in FY2025.

Key figures

Market cap $2.7M · P/S ratio 1.05 · EPS (TTM) $−1,831 · Return on equity −105% · Return on assets (EBIT) −62.5% · Operating margin −290% · Revenue growth (YoY) −45.8% · Free cash flow −$6.4M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 100% below its 52-week high and 4% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −43%, ELAB screens richer than that median.

Fair Value models

Bear $1.28 Fair Value $1.93 Bull $2.41
Price $3.36 · Upside -42.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $4.84 $6.49 $9.68 51
All 1 models by family
Asset-Based
NCAV (Graham) $4.84 $6.49 $9.68 51

Open the full fair value analysis →

Notify me when ELAB reaches fair value

Put ELAB on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 19/100

Of which business quality 19 · Market factors (momentum, volatility) 15

Profitability 0
Margins and returns on capital today
Quality Growth 20
Are margins and returns improving?
Cashflow 6
Earnings quality: real cash, not paper profit
Fin. Strength 73
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−76.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−94,928.7% (2021) → −1,250.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ELAB screens overvalued: fair value 43% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Elevai Labs, Inc. Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 607 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 19 · Bottom 25%
Fair Value upside −42.6% · Above median
Profitability
Return on assets −33.0% · Bottom 25%
Growth and dividend
Revenue growth −45.8% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.35× · Cheapest 25%
P/S (TTM) 1.06× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $504.73 $555.20 +10%
Regeneron Pharmaceuticals, Inc REGN $735.20 $1,275 +73%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Elevai Labs, Inc. Common Stock · Fair Value
$1.93 −43%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Elevai Labs, Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/ELAB

Frequently asked questions

Is Elevai Labs, Inc. (ELAB) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of $1.93 versus a price of $3.36, about −43% upside (overvalued).
What is the fair value of ELAB?
Our model-based fair value for Elevai Labs, Inc. Common Stock is $1.93 (as of Oct 4, 2026), built from audited fundamentals. The current price: $3.36.
What is the quality score of ELAB?
Elevai Labs, Inc. Common Stock has a Quality Score of 19/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Elevai Labs, Inc. (ELAB)?
Our model-based price target is the fair value of $1.93 (as of Oct 4, 2026) from 1 valuation models. Cautious scenario $1.28, optimistic scenario $2.41. It is a calculation from audited fundamentals, not an analyst target.
What is the Elevai Labs, Inc. Common Stock stock forecast for 2026?
Our models put fair value at $1.93, about −43% upside versus a price of $3.36 (overvalued). Cautious scenario $1.28, optimistic scenario $2.41. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Elevai Labs, Inc. (ELAB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Elevai Labs, Inc. Common Stock it is $1.93 per share (as of Oct 4, 2026), against a price of $3.36. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Elevai Labs, Inc. Common Stock stock overvalued or undervalued in 2026?
As of Oct 4, 2026, ELAB trades above its calculated fair value: price $3.36, fair value $1.93, a gap of about −43% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ELAB?
No. The price is what the market pays today ($3.36); the fair value is what the company's own numbers justify ($1.93). For Elevai Labs, Inc. Common Stock the two are $1.43 per share apart. That gap is exactly why we show both numbers side by side.
How much is Elevai Labs, Inc. Common Stock worth?
The market values Elevai Labs, Inc. Common Stock at about $2.7M (market capitalisation, as of Oct 4, 2026). Per share that is $3.36; our models calculate a fair value of $1.93 per share.
What do the bullish and bearish scenarios say about ELAB?
Our models span a range for Elevai Labs, Inc. Common Stock: cautious scenario $1.28, base $1.93, optimistic $2.41 per share (as of Oct 4, 2026, price $3.36). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Elevai Labs, Inc. (ELAB)?
Balance-sheet figures for Elevai Labs, Inc. Common Stock (as of Oct 4, 2026): return on equity −105.2%. They feed the Quality Score of 19/100, which measures business quality independently of the share price.
How far is ELAB from its 52-week high?
Elevai Labs, Inc. Common Stock trades at $3.36, about 100% below its 52-week high of $2,167 and 4% above the low of $3.23 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $1.93 is for.
Which stocks are comparable to Elevai Labs, Inc. Common Stock?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Elevai Labs, Inc. Common Stock stock attractive at the current price?
The data as of Oct 4, 2026: price $3.36, calculated fair value $1.93 (−43%), Quality Score 19/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ELAB calculated?
We run Elevai Labs, Inc. Common Stock through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.93, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Elevai Labs, Inc. Common Stock itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Elevai Labs, Inc. (ELAB)?
The closing price on Oct 2, 2026 was $3.36. Our model-based fair value is $1.93, about −43% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Elevai Labs, Inc. Common Stock right now?
The price sits above even our optimistic bull case ($2.41). The favourable scenario is already priced in. Weak quality (19/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($1.28 to $2.41) leaves room in how you read the outcome.

Key figures of Elevai Labs, Inc. Common Stock

How large is the market capitalisation of Elevai Labs, Inc. (ELAB)?
The market capitalisation of Elevai Labs, Inc. Common Stock is $2.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Elevai Labs, Inc. (ELAB)?
The price-to-sales ratio of Elevai Labs, Inc. Common Stock is 1.05 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Elevai Labs, Inc. (ELAB)?
Earnings per share at Elevai Labs, Inc. Common Stock are $−1,831. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Elevai Labs, Inc. (ELAB)?
The return on equity (ROE) of Elevai Labs, Inc. Common Stock is −105% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Elevai Labs, Inc. (ELAB)?
On an EBIT basis the return on assets of Elevai Labs, Inc. Common Stock is −62.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Elevai Labs, Inc. (ELAB)?
The operating margin of Elevai Labs, Inc. Common Stock is −290% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Elevai Labs, Inc. (ELAB)?
Revenue at Elevai Labs, Inc. Common Stock is growing −45.8% versus a year earlier (3y avg −8.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Elevai Labs, Inc. (ELAB) generate?
The free cash flow of Elevai Labs, Inc. Common Stock is −$6.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Elevai Labs, Inc. (ELAB) hold?
Elevai Labs, Inc. Common Stock holds more cash than debt, $2.8M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Elevai Labs, Inc. Common Stock in the live analysis

One click puts Elevai Labs, Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.